DCb (Docetaxel/Carboplatin) Versus EC-D (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer

NCT03154749 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

93

Enrollment

OTHER

Sponsor class

Conditions

Triple-Negative Breast Cancer

Interventions

DRUG: DCb (docetaxel/carboplatin) versus EC followed by D (epirubicin/cyclophosphamide followed by docetaxe)

Sponsor

Guangdong Provincial People's Hospital

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]